Loading patent…
AssigneeVivus, Inc.
InventorsVirgil A. Place, Leland F. Wilson, Paul C. Doherty, Jr., Mark S. Hanamoto, Alfred P. Spivack, Neil Gesundheit, Sean R. Bennett
Estimating the term…
Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.
A method for treating sexual dysfunction in a female individual, comprising administering to the vagina and/or vulvar area of the individual a pharmaceutical formulation that comprises an effective amount of a vasoactive agent selected from the group consisting of a Type V phosphodiesterase inhibitor, pharmaceutically acceptable salts, esters, analogs, derivatives, prodrugs and inclusion complexes thereof, and combinations of any of the foregoing.
A method for improving vaginal muscle tone and tissue health in a female individual, comprising vaginally administering to such individual a pharmaceutical formulation that comprises a vasoactive agent selected from the group consisting of a Type V phosphodiesterase inhibitor, pharmaceutically acceptable salts, esters, analogs, derivatives, prodrugs and inclusion complexes thereof, and combinations of any of the foregoing, in combination with a pharmaceutically acceptable carrier.
A method for enhancing vaginal lubrication in a female individual, comprising vaginally administering to such individual a pharmaceutical formulation that comprises a vasoactive agent selected from the group consisting of a Type V phosphodiesterase inhibitor, pharmaceutically acceptable salts, esters, analogs, derivatives, prodrugs and inclusion complexes thereof, and combinations of any of the foregoing, in combination with a pharmaceutically acceptable carrier.
A method for treating sexual dysfunction in a female individual, comprising administering to the vagina and/or vulvar area of the individual (a) a therapeutically effective amount of a Type V phosphodiesterase inhibitor or a pharmaceutically acceptable salt or ester thereof, and (b) a therapeutically effective amount of an additional active agent selected from the group consisting of additional vasodilators, androgenic agents, and combinations thereof.
Dependencies are inferred from the claim text.